We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nathan Wong


Professor and Director, Heart Disease Prevention Program, Division of Cardiology at the University of California Irvine, Irvine, California

Dr. Nathan Wong is a cardiovascular epidemiologist, specialist in preventive cardiology, and Professor and Director, Heart Disease Prevention Program, Division of Cardiology at the University of California, Irvine in California, with joint appointments in Epidemiology and UCLA and UC Irvine. He holds MPH and PhD degrees in epidemiology from Yale University and is a fellow of the American College of Cardiology, American Heart Association, National Lipid Association, and American Society for Preventive Cardiology (ASPC).  He is currently president of the Interamerican Heart Foundation, focusing on cardiovascular health promotion in Latin America, and is a past president of the ASPC and Pacific Lipid Association. Dr. Wong has primary research interests in the epidemiology of subclinical atherosclerosis, including vascular calcification, as well as epidemiology and management of dyslipidemia, diabetes, and cardiovascular disease.  He has participated as an investigator or collaborator on key prospective studies, including the Framingham Heart Study, Cardiovascular Health Study, Multiethnic Study of Atherosclerosis, and Women’s Health Initiative.  He has authored over 350 papers and co-edited seven textbooks.


Dr. Wong reports the following:
  • Research contracts through institution from NovoNordisk, Boehringer Ingelheim, Novartis, Esperion, Amarin, and Amgen
  • Consultant for Novartis
  • Speakers Bureau for Amarin and Esperion